Anxiety and substance use: layers of complexity

References

• Thomas SE, Randall CL, Carrigan MH. Drinking to cope in socially anxious individuals: a controlled study. Alcohol. Clin. Exp. Res.27, 1937–1943 (2003).
   PubMed Web of Science ®Google Scholar
• Castle DJ, Solowij N. Acute and subacute psychomimetic effects of cannabis in humans. In: Marijuana and Madness. Castle DJ, Murray RM (Eds). Cambridge University Press, Cambridge, UK, 41–53 (2004).
   Google Scholar
• Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by δ-9-tetrahydrocannbinol. Psychopharmacology163, 111–117 (2002).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition, Revised). American Psychiatric Publishing Inc., DC, USA (1994).
   Google Scholar
• Kessler RC, Nelson CB, McDonagle KA et al. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilisation. Am. J. Orthopsychiatry66, 17–31 (1996).
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA264, 2511–2518 (1990).
   PubMed Web of Science ®Google Scholar
• Kushner MG, Sher KJ, Beitman BD. The relation between alcohol problems and the anxiety disorders. Am. J. Psychiatry147, 685–695 (1990).
   PubMed Web of Science ®Google Scholar
• Grant B, Stinson F, Dawson D et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders. Arch. Gen. Psychiatry61, 807–816 (2004).
   PubMed Web of Science ®Google Scholar
• Swift R, Mueller T. Treatment of anxiety in substance abuse and dependence. In: Addictive Disorders in the Mentally and Physically Disabled. Hubbard J, Martin T (Eds). Marcel Dekker, NY, USA 11–32 (2001).
   Google Scholar
• Weissman MM, Klerman GL, Markowitz JS, Ouelette R. Suicidal ideation and suicide attempts in panic disorder and attacks. N. Engl. J. Med.321, 1209–1214 (1989).
   PubMed Web of Science ®Google Scholar
• Kushner MG, Abrams K, Thuras P et al. Follow up study of anxiety disorder and alcohol dependence in comorbid alcoholism treatment patients. Alcohol. Clin. Exp. Res.29, 1432–1443 (2005).
   PubMed Web of Science ®Google Scholar
• Bossavo G. The long-term treatment outcomes of depression and anxiety comorbid with substance abuse. J. Behav. Health Serv. Res.28, 42–57 (2001).
   PubMed Web of Science ®Google Scholar
• Hornig CD, McNally RJ. Panic disorder and suicide attempt: a reanalysis of data from the Epidemiologic Catchment Area study. Br. J. Psychiatry167, 76–80 (1995).
   PubMed Web of Science ®Google Scholar
• Ramirez J. Chemical addictions and anxiety disorders: when adaptive mechanisms go awry. In: Managing the Dually Diagnosed Patient: Clinical Issues and Clinical Approaches (2nd Edition) O’Connell D, Beyer E (Eds).The Hawthorn Press, NY, USA 239–286 (2002).
   Google Scholar
• Stewart S, Conrad P. Psychosocial models of functional associations between posttraumatic stress disorder and substance use disorder. In: Trauma and Substance Abuse: Causes, Consequences and Treatment of Comorbid Disorders. Ouimette P, Brown PJ (Eds). American Psychiatric Association, Washington, DC, USA 29–56 (2003).
   Google Scholar
• Wyman K, Castle DJ. Anxiety and substance use disorder comorbidity: prevalence, explanatory models and treatment implications. J. Dual Diagnosis2, 93–119 (2006).
   Google Scholar
• Kendler KS, Davis CG, Kessler RC. The familial aggregation of common psychiatric and substance use disorders in the National Comorbidity Survey: a family history study. Br. J. Psychiatry170, 541–548 (1997).
   PubMed Web of Science ®Google Scholar
• Kushner M, Thuras P, Abrams L, Brekke M. Anxiety mediates the association between anxiety sensitivity and coping-related drinking motives in alcoholism treatment patients. Addict. Behav.26, 869–885 (2001).
   PubMed Web of Science ®Google Scholar
• Kushner MG, Sher KJ, Beitman BD. The relation between alcohol problems and the anxiety disorders. Am. J. Psychiatry147, 685–695 (1990).
   PubMed Web of Science ®Google Scholar
• Breresford TP, Blow KC, Singer K, Lucey MR. Clinical practice: comparison of CAGE questionnaire and computer assisted laboratory profiles in screening for covert alcoholism. Lancet336, 482–485 (1990).
   PubMed Web of Science ®Google Scholar
• Selzer ML. The Michigan Alcoholism Screening Test: the quest for a new diagnostic instrument. Am. J. Psychiatry127, 1653–1658 (1971).
   PubMed Web of Science ®Google Scholar
• Bohn MJ, Babor TF, Krantzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J. Stud. Alcohol56, 423–432 (1995).
   PubMed Web of Science ®Google Scholar
• Cocco Km, Carey KB. Psychometric properties of the Drug Abuse Screening Test in psychiatric outpatients. Psychol. Assess.10, 408–414 (1998).
   Web of Science ®Google Scholar
• Kranzler HR, Kadden RM, Babor TF et al. Validity of the SCID in substance abuse patients. Addiction91, 859–868 (1996).
   PubMed Web of Science ®Google Scholar
• Hasin DS, Trautman KD, Miele GM et al. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): relaibility for substance abusers. Am. J. Psychiatry153, 1195–1201 (1996).
   PubMed Web of Science ®Google Scholar
• Prochaska JO, DiClementi CC. The Transtheoretical Approach: Crossing Traditional Boundaries Of Therapy. Dow Jones–Irwin, IL, USA (1984).
   Google Scholar
• Osher FC, Koefoed LL. Treatment of patients with psychiatric and psychoactive substance use disorders. Hosp. Community Psychiatry40, 1025–1030 (1989).
   PubMedGoogle Scholar
• Najavatis LM, Weiss RD, Shaw SR, Muenz LR. “Seeking safety” outcome of a new cognitive behavioural psychotherapy for women with posttraumatic stress disorder and substance dependence. J. Trauma. Stress11, 437–456 (1998).
   PubMed Web of Science ®Google Scholar
• Zlotnick C, Najavitz LM, Rohsenow D, Johnson DM. A cognitive–behavioral treatment for incarcerated women with substance use disorder and posttraumatic stress disorder: findings from a pilot study. J. Subst. Abuse Treat.25, 99–105 (2003).
   PubMed Web of Science ®Google Scholar
• Donovan B, Padin-Rivera E, Kowaliw S. “Transcend”: initial outcomes from a posttraumatic stress disorder/substance abuse disorder program. J. Trauma. Stress14, 757–772 (2001).
   PubMed Web of Science ®Google Scholar
• Triffleman E. Gender differences in a controlled pilot study of psychosocial treatments in substance dependent patients with post-traumatic stress disorder; design considerations and outcomes. Alcohol Treat. Q.18, 113–126 (2000).
   Google Scholar
• Brady KT, Dansky BS, Back SE et al. Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: preliminary findings. J. Subst. Abuse Treat.21, 47–54 (2001).
   PubMed Web of Science ®Google Scholar
• Bowen RC, D’Arcy C, Keehan D, Senthilselvan A. A controlled trial of cognitive behavioural treatment of panic in alcoholic inpatients with comorbid panic disorder. Addict. Behav.25, 593–597 (2000).
   PubMed Web of Science ®Google Scholar
• Randall CL, Thomas S, Thevos AK. Concurrent alcoholism and social anxiety disorders: a first step toward developing effective treatments. Alcohol. Clin. Exp. Res.25, 210–220 (2001).
   PubMed Web of Science ®Google Scholar
• Fals-Stewart W, Schafer J. The treatment of substance abusers diagnosed with obsessive compulsive disorder: an outcome study. J. Subst. Abuse Treat.9, 365–370 (1992).
   PubMed Web of Science ®Google Scholar
• Nunes EV, McGrath PJ, Quitkin FM. Treating anxiety in patients with alcoholism. J. Clin. Psychiatry56(Suppl. 2), 3–9 (1995).
   PubMed Web of Science ®Google Scholar
• Dunner D. Management of anxiety disorders: the added challenge of comorbidity. Depress. Anxiety13, 57–71 (2001).
   PubMed Web of Science ®Google Scholar
• Gorelick DA. Serotonin uptake blockers and the treatment of alcoholism. Recent Dev. Alcohol.7, 262–281 (1989).
   Google Scholar
• Frances RJ, Borg L. The treatment of anxiety in patients with alcoholism. J. Clin. Psychiatry54(Suppl. 5), 37–43 (1993).
   PubMed Web of Science ®Google Scholar
• Brady KT, Sonne SC, Roberts JM. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J. Clin. Psychiatry56, 502–505 (1995).
   PubMed Web of Science ®Google Scholar
• Randall CL, Thomas S, Thevos AK. Concurrent alcoholism and social anxiety disorders: a first step toward developing effective treatments. Alcohol. Clin. Exp. Res.25, 210–220 (2001).
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Burleson JA, Del Boca FK et al. Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch. Gen. Psychiatry51, 720–731 (1994).
   PubMed Web of Science ®Google Scholar
• McRae AL, Sonne SC, Brady KT. The use of buspirone for the treatment of persistent anxiety in methadone-maintained patients. Am. J. Addict. (2003) (In Press)..
   Google Scholar
• Malcolm R, Anton RF, Randall CL et al. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol. Clin. Exp. Res.16, 1007–1013 (1992).
   PubMed Web of Science ®Google Scholar
• Myrick H, Brady K. Current review of the comorbidity of affective, anxiety, and substance use disorders. Curr. Opin. Psychiatry16, 261–270 (2003).
   Web of Science ®Google Scholar
• Louie AK, Lannon RA, Ketter TA. Treatment of cocaine-induced panic disorder. Am. J. Psychiatry146, 40–44 (1989).
   PubMed Web of Science ®Google Scholar
• Keuneman R, Pokos V, Weerasundera R, Castle DJ. Antipsychotic treatment in obsessive-compulsive disorder: a literature review. Aust. NZ J. Psychiatry39, 336–343 (2005).
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Amin H, Modesto-Lowe V, Oncken C. Pharmacologic treatments for drug and alcohol dependence. Psychiatr. Clin. North Am.22, 401–423 (1999).
   PubMed Web of Science ®Google Scholar
• Viveros MP. Psychoneuroendocrine effects of cannabinoids in critical developmental periods. Presented at: European College of Neuropsychopahmacology Congress. Vienna, Austria, 13–17 October 2007.
   Google Scholar
• Bortolato M, Campolono P, Mangieri RA et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology31, 2652–2659 (2006).
   PubMed Web of Science ®Google Scholar
• Kamprath K, Marsicano G, Tang J et al. Cannabinoid CB1 receptor mediates fear extinction via habituation-like process. J. Neurosci.26, 6677–6686 (2006).
   PubMed Web of Science ®Google Scholar
• Sundram S, Castle D. Cannabis and the brain. In: Translation of Addictions Science into Practice. Miller PM, Kavanagh DJ (Eds). Elsevier, Amsterdam, 81–102 (2007).
   Google Scholar
• Navarro JF, Maldonado E. Acute and subchronic effects of MDMA (“ecstacy”) on anxiety in male mice tested the elevated plus-maze. Prog. Neuropsychopharmacol. Biol. Psychiatry26, 1151–1154 (2002).
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang G-J, Beleiter H et al. Regional brain metabolic metabolic response to lorazepam in subjects at risk for alcoholism. Alcohol. Clin. Exp. Res.19, 510–516 (1995)
   PubMed Web of Science ®Google Scholar
• Pandey SC, Zhang H, Roy A, Xu T. Deficits in amygdaloid cAMP-responsive element-binding protein signalling play a role in genetic predisposition to anxiety and alcoholism. J. Clin. Invest.115, 2762–2773 (2005).
   PubMed Web of Science ®Google Scholar
• Pandey SC, Roy A, Zhang H, Xu T. Partial deletion of the cAMP response element-binding protein gene promotes alcohol-drinking behaviors. J. Neurosci.24, 5022–5030 (2004).
   PubMed Web of Science ®Google Scholar
• Pandey SC. Anxiety and alcohol abuse disorders: a common role for CREB and its target, the neuropeptide Y gene. Trends Pharmacol. Sci.24, 456–460 (2003).
   PubMed Web of Science ®Google Scholar
• Pandey SC, Zhang H, Roy A, Misra K. Central and medial amygdaloid brain-derived neurotrophic factor signalling plays a critical role in alcohol-drinking and anxiety-like behaviors. J. Neurosci.26, 8320–8331 (2006).
   PubMed Web of Science ®Google Scholar
• Carvajal C, Dumont Y, Quirion R. Neuropeptide Y: role in emotion and alcohol dependence. CNS Neurol. Disord. Drug Targets5, 181–195 (2006).
   PubMedGoogle Scholar
• Holmes A, Picciotto MR. Galanin: a novel therapeutic target for depression, anxiety disorders, and drug addiction? CNS Neurol. Disord. Drug Targets5, 225–232 (2006).
   PubMedGoogle Scholar
• Buydens-Branchley L, Branchley M. n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers. J. Clin. Psychopharmacol.26, 661–665 (2006).
   PubMed Web of Science ®Google Scholar